13 research outputs found
High salivary-gland ultrasonography grade and high focus score predict the response to rituximab.
<p>SGUS, salivary gland ultrasonography; UWSF, unstimulated whole salivary flow. The response was assessed using the SSRI-30 (Sjögren’s Syndrome Response Index 30), defined as an at least 30% improvement from baseline to week 24 in at least two of the following five criteria: fatigue visual analogue scale [VAS], oral dryness VAS, ocular dryness VAS, unstimulated whole salivary flow, and erythrocyte sedimentation rate.</p
Salivary-gland ultrasonography grade correlates with salivary flow and histology.
<p>SGUS, salivary gland ultrasonography; UWSF, unstimulated whole salivary flow. The total SGUS grade obtained by summing the grades of the two parotid and two submandibular glands can range from 0 to 16.</p
Kaplan-Meier plots of the risk of disease relapse following rituximab in 31 IgG4-RD responding patients.
<p>Kaplan-Meier plots of the risk of disease relapse following rituximab in 31 IgG4-RD responding patients.</p
Kaplan-Meier plots of the risk of disease relapse following rituximab for patients with IgG4-RD RI >9 and with IgG4-RD RI ≤9 at RTX treatment.
<p>IgG4-RD RI, IgG4-related disease Responder Index.</p
Clinical, biological and radiological efficacy of RTX in 33 patients with IgG4-RD.
<p>Clinical, biological and radiological efficacy of RTX in 33 patients with IgG4-RD.</p
Number of patients in the ASSESS cohort fulfilling each inclusion criteria set.
<p>First step: AECG criteria. Second step: systemic disease (ESSDAIhigher to 2). Third step: disease duration less than 4 years. Fourth step: More than two VAS/3 higher to 50/100 mm. Fifth step: biological activity (pSS, primary Sjögren’s syndrome; AECG, American-European Consensus Group; ESSDAI, EULAR Sjögren Syndrome Disease Activity Index; VAS, visual analog scale (100-mm line); BA, biological activity).</p
Open-label therapeutic trials of biologics in primary Sjögren’s disease reported between 2002 and 2014.
<p>N, number of patients; pSS, primary Sjögren’s syndrome; AECG: American-European Consensus Group criteria for primary Sjögren’s syndrome; SGB, salivary-gland biopsy; Ig, immunoglobulin; MALT, mucosa-associated lymphoid tissue; ESR, erythrocyte sedimentation rate; VAS, visual analogue scale (0–100 mm); RF, rheumatoid factor; MFI, Multidimensional Fatigue Inventory; C4, fraction 4 of complement; ESSDAI, European League Against Rheumatism (EULAR) Sjögren's Syndrome Disease Activity Index; ESSPRI, EULAR Sjögren's Syndrome Patient Reported Index; SF-36, Short-Form 36-item quality of life questionnaire; SGUS, salivary-gland ultrasound; NA, not applicable; BELISS: Belimumab in primary Sjögren’s Syndrome</p><p>Open-label therapeutic trials of biologics in primary Sjögren’s disease reported between 2002 and 2014.</p
Controlled therapeutic trials of biologics in primary Sjögren’s syndrome reported between 2002 and 2014.
<p>TRIPPS: Trial of Remicade In Primary Sjogren's Syndrome; TEARS: Tolerance and EfficAcy of Rituximab in primary Sjögren syndrome; TRACTISS, Trial of Anti-B-Cell Therapy In primary Sjögren’s Syndrome; ETAP: Efficacy of Tocilizumab in Primary Sjögren's Syndrome; AECG, American-European Consensus Group criteria for primary Sjögren’s syndrome; ESR, erythrocyte sedimentation rate; Ig, immunoglobulin; pSS, primary Sjögren’s syndrome; VAS, visual analogue scale (0–100 mm); RF, rheumatoid factor; SGB: salivary gland biopsy; ESSDAI, European League Against Rheumatism (EULAR) Sjögren's Syndrome Disease Activity Index; N, number of patients.</p><p>Controlled therapeutic trials of biologics in primary Sjögren’s syndrome reported between 2002 and 2014.</p